Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 7, 2008, Pages 1257-1265

  Gross, Volker ^a  

^a KLINIKUM ST MARIEN   (Germany)

Author keywords

Budesonide; Collagenous colitis; Crohn's disease; Induction of remission; Lymphocytic colitis; Maintenance of remission; Ulcerarive colitis

Indexed keywords

AZATHIOPRINE; BUDENOFALK; BUDESONIDE; DEXAMETHASONE; ENEMA; GLUCOCORTICOID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; ANTIINFLAMMATORY AGENT;

ACNE; ARTICLE; ASCENDING COLON; CATARACT; CLINICAL TRIAL; COLLAGENOUS COLITIS; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FIRST PASS EFFECT; GLAUCOMA; HUMAN; HYPERTENSION; ILEUM; LOW DRUG DOSE; LYMPHOCYTIC COLITIS; MOON FACE; PH; PH MODIFIED RELEASE FORMULATION; RELAPSE; REMISSION; SIDE EFFECT; SKIN DISEASE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ORAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CLINICAL TRIALS AS TOPIC; COLITIS, COLLAGENOUS; COLITIS, LYMPHOCYTIC; DELAYED-ACTION PREPARATIONS; GLUCOCORTICOIDS; HUMANS; HYDROGEN-ION CONCENTRATION; INFLAMMATORY BOWEL DISEASES;

EID: 43049164217     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.7.1257     Document Type: Article

References (50)

1. Tromm A, Möllmann HW, May B. Glucocorticoid treatment of inflammatory bowel diseases: summary of previous studies. In: Möllmann HW, May B, editors, Glucocorticoid therapy in chronic inflammatory bowel disease. Kluwer Academic Publishers: Dordrecht, Boston, London; 1996. p. 15-41
2. Malchow H, Ewe K, Brandes JW, et al.; European Crohn's Disease Study (ECCDS). Results of drug treatment. Gastroenterology 1984;86:249-66
3. Tromm A, Möllmann HW, May B. Glucocorticoid therapy practice in inflammatory bowel disease. Results of a survey of German therapeutic centres. In: Möllmann HW, May B, editors, Glucocorticoid therapy in chronic inflammatory bowel disease. Kluwer Academic Publishers: Dordrecht, Boston, London; 1996. p. 1-14
4. Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 2005;57:303-16
5. Marin-Jimenez I, Pena AS. Budesonide for ulcerative colitis. Rev Esp Enferm Dig 2006;98:362-73
6. Ryrefeldt A, Andersson P Edsbäcker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;63(Suppl 122):86-95
7. Edsbäcker S, Bengtsson B, Larsson P, et al. A pharmacoscintigraphic avaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 2003;17:525-36
8. Möllmann HW, Barth J, Hochhaus G, et al. Principles of topical versus systemic corticoid treatment in inflammatory bowel disease. In: Möllmann HW, May B, editors, Glucocorticoid therapy in chronic inflammatory bowel disease. Kluwer Academic Publishers: Dordrecht, Boston, London; 1996. p. 42-60
9. Roth M, Gross V, Schölmerich J, et al. Treatment of active Crohn's disease with an oral slow-release budesonide formulation. Am J Gastroenterol 1993;88:968-9
10. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-merhylprednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:905-9
11. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1996;115:835-40
12. Herfarth H, Gross V, Andus T, et al. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization. Int J Colorectal Dis 2004;19:147-52
13. Andus T, Gross V, Caesar I, et al. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease. Results of an open, prospective, multicenter trial. Dig Dis Sci 2003;48:373-8
14. Steinhart AM, Ewe K, Griffith AM, et al. Corticosteroids for maintaining remission of Crohn's disease. Cochrane Libray, Issue 4 Oxford. Update Software, 2003
15. Gross V, Andus T, Ecker KW, et al. Low dose oral pH-modified release budesonide for maintenance of steroid induced remission in Crohn's disease. Gut 1998;42:493-6
16. De Jong DJ, Bac DJ, Tan G, et al. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission. Neth J Med 2007;65:339-45
17. Ewe K Böttger T, Buhr HJ, et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. Eur J Gastroenterol Hepatol 1999;11:277-82
18. Dilger K, Alberer M, Busch A, et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment Pharmacol Ther 2006;23:387-95
19. Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002;140:75-80
20. Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2003;36:248-52
21. Kolkman JJ, Möllmann HW, Möllmann AC, et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today 2004;40:589-601
22. Keller R, Stoll R, Foerster EC, et al. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment Pharmacol Ther 1997;11:1047-52
23. Tromm A, Griga T, Möllmann HW, et al. Budesonide for the treatment of collagenous colitis: First results of a pilot trial. Am J Gastroenterol 1999;94:1871-5
24. Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002;122:20-5
25. Baert F. The role of budesonide in the treatment of collagenous and lymphocytic colitis. In: Dignass A, Gross V, Buhr AJ, James OFW, editors, Topical steroids in gastroenterology and hepatology. Kluwer Academic Publishers: Dordrecht, NL; 2004. p. 47-56
26. Miehlke S, Madisch A, Bethke B, et al. Budesonide in lymphocytic colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2007;132(4 Suppl 2):A-131
27. Madisch A, Wonschik S, Morgner A, et al. Long-term follow-up of lymphocytic colitis after induction of clinical remission with budesonide. Gastroenterology 2007;132(4 Suppl 2):A-511
28. Kane SV, Schoenfeld P, Sandborn WJ, et al. Systematic review: The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 2002;16:1509-17
29. Greenberg GR, Feagan BG, Martin F, et al.; and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41
30. Tremaine WJ, Hanauer SB, Katz S, et al.; and the Budesonide CIR United States Study Group. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-54
31. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5
32. Campieri M, Ferguson A, Doe W, et al.; and the Global Budesonide Study Group: Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997;41:209-14
33. D'Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998;12:419-24
34. Thomson OS, Cortot A, Jewell D, et al.; and the International Budesonide-Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 1998;339:370-4
35. Stange EF, Travis SPL, Vermeire S, et al. ECCO consensus on the management of Crohn's disease. Gut 2006;55(Suppl 1):i1-58
36. Cortot A, Colombel J-F, Rutgeerts P, et al.; for the International Budesonide Study Group. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut 2001;48:186-90
37. Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 1996;39:82-6
38. Greenberg GT, Feagan BG, Martin F, et al.; and the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide as maintenance treatment for Crohn's disease. a placebo-controlled, dose-ranging study. Gastroenterology 1996;110:45-51
39. Ferguson A, Campieri M, Doe W, et al.; and the Global budesonide Study Group. Oral budesonide as maintenance therapy in Crohn's disease - results of a 12-month study. Aliment Pharmacol Ther 1998;12:175-83
40. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005;21:363-71
41. Green JR, Lobo AJ, Giaffer M, et al. and the Freedom Investigator Group: Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. Aliment Pharmacol Ther 2001;15:1331-41
42. Hellers G, Cortot A, Jewell D, et al.; and the IOIBD Budesonide Study Group. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology 1999;116:294-300
43. Sandborn WJ, Löfberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100:1780-7
44. Gross V, Bar-Meir S, Lavy A, et al.; and the International Budesonide Foam Study Group. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006;23:303-12
45. Bar-Meir S, Fidder HH, Faszczyk M, et al.; and The International Budesonide Study Group. Budesonide foam vs. hydrocordsone acetate foam in the treatment of active ulcerative proctosigmoiditis. Dis Col Rect 2003;46(7):929-36
46. Chopra A, Pardi DS, Loftus EV, et al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis 2006;12:29-32
47. Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007;25:1231-6
48. Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002;123:978-84
49. Bonderup OK, Hansen JB, Barket-Smith L, et al. Budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial with morphometric analysis. Gut 2003;52:248-51
50. Feyen B, Wall GC, Finnerty EP, et al. Meta-analysis: budesonide treatment for collagenous colitis. Aliment Pharmacol Ther 2004;20:745-9